%0 Journal Article %T Preliminary study of the treatment effect of apatinib mesylate upon malignant ascites and its safety %A Liu, Changmin %A Chen, Shaoshui %A Wang, Ping %A Geng, Dianzhong %A Zhang, Weiming %A Yang, Jing %A Luo, Judong %A Ning, Fangling %J Translational Cancer Research %D 2017 %B 2017 %9 %! Preliminary study of the treatment effect of apatinib mesylate upon malignant ascites and its safety %K %X Background: This paper reports the effect of combining oral apatinib and abdominal cavity perfusion with cis-platinum for malignant ascites and its safety. Methods: Seventeen malignant ascite patients were treated with oral apatinib (500 mg/d) and abdominal cavity perfusion of 60 mg/m2 cis-platinum (apatinib group), and 12 patients were treated with cis-platinum (60 mg/m2) only (control group). Twenty-one days was deemed as a cycle for both groups. Short-term treatment effects, quality of life (QOL), and toxicity were evaluated. Enzyme-linked immunosorbent assay (ELISA) was used to determine the vascular endothelial growth factor (VEGF) level in ascites. Results: The response rates in apatinib and control groups were 70.6% and 33.3% (P 0.05). In the control group, no statistical difference was found in any parameter (P>0.05). The most common grade 3 or more severe adverse effects (AEs) in the apatinib group were fatigue and hypertension with 70.6% and 41.2% incidence rates, respectively. In the apatinib group, four patients suffered from intestinal obstruction, with two developing complete intestinal obstruction. However, in the control group, none suffered from intestinal obstruction. Conclusions: A combination of apatinib and cis-platinum can improve short-term response rate of malignant ascites, enhance QOL and control adverse drug effects. VEGF level in the abdominal cavity may be a good predictor of treatment efficacy. %U https://tcr.amegroups.org/article/view/16172 %V 6 %N 5 %P 894-900 %@ 2219-6803